Clinical Trial Update: NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating NB02 (Poseltinib) in combination with Rituximab and Lenalidomide for relapsed/refractory Primary Central Nervous System Lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• NB02 (Poseltinib) (Poseltinib)
• Rituximab (rituximab)

Snippet

Sponsor: NOBO Medicine | Conditions: Primary CNS Lymphoma (PCNSL) | Phase 2 | Status: RECRUITING